Table 2.
Change in characteristics at week 12.
| Placebo n = 62 |
Empagliflozin n = 62 |
|
|---|---|---|
| SBP (adjusted mean over 24 h), mmHg | 147.5 (0.77) | 144.3 (0.77) |
| Change from baseline | 0.41 (0.23) | − 7.73 (0.23) |
| Difference vs. placebo | − 8.14 (1.01) | |
| 95% CI | − 10.32, − 3.96 | |
| P | 0.005 | |
| DBP (adjusted mean over 24 h), mmHg | 94.4 (0.68) | 89.1 (0.68) |
| Change from baseline | 0.14 (0.09) | − 5.13 (0.09) |
| Difference vs. placebo | − 5.27 (0.07) | |
| 95% CI | − 8.19, − 1.35 | |
| P | < 0.001 | |
| SBP (office measurement), mmHg | 155.0 (0.78) | 147.9 (0.78) |
| Change from baseline | − 0.36 (0.12) | − 6.63 (0.13) |
| Difference vs. placebo | − 6.27 (0.11) | |
| 95% CI | − 9.37, − 1.97 | |
| P | < 0.001 | |
| DBP (office measurement), mmHg | 96.4 (0.70) | 90.9 (0.70) |
| Change from baseline | − 0.07 (0.09) | − 4.54 (0.09) |
| Difference vs. placebo | − 4.47 (1.01) | |
| 95% CI | − 7.41, − 0.47 | |
| P | < 0.001 | |
| HbA1c, % | 7.6 (0.07) | 7.4 (0.07) |
| Change from baseline | 0.1 (0.09) | − 0.5 (0.09) |
| Difference vs. placebo | − 0.6 (0.11) | |
| 95% CI | − 0.83, − 0.42 | |
| P | < 0.001 | |
| Body weight, kg | 76.4 (0.61) | 79.6 (0.61) |
| Change from baseline | − 1.2 (0.99) | − 7.9 (0.99) |
| Difference vs. placebo | − 6.7 (0.86) | |
| 95% CI | − 8.45, − 5.03 | |
| P | < 0.001 | |
| HOMA-IR | 4.9 (0.15) | 4.5 (0.15) |
| Change from baseline | − 0.3 (0.09) | − 1.8 (0.09) |
| Difference vs. placebo | − 1.5 (0.12) | |
| 95% CI | − 1.90, − 1.06 | |
| P | < 0.001 |